AstraZeneca plc (LON:AZN) Given Average Rating of “Hold” by Analysts

Shares of AstraZeneca plc (LON:AZN) have received an average rating of “Hold” from the thirty brokerages that are covering the firm, Market Beat reports. Four research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation and fourteen have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is GBX 4,858.76 ($72.30).

In related news, insider Courtois,Jean-Philippe purchased 900 shares of AstraZeneca plc stock in a transaction on Tuesday, October 27th. The shares were purchased at an average price of GBX 4,423 ($65.82) per share, for a total transaction of £39,807 ($59,236.61).

Shares of AstraZeneca plc (LON:AZN) traded down 2.6102% on Monday, hitting GBX 4496.0000. The company had a trading volume of 1,051,870 shares. The firm has a 50-day moving average price of GBX 4,427.61 and a 200 day moving average price of GBX 4,259.49. AstraZeneca plc has a 12-month low of GBX 3,746.00 and a 12-month high of GBX 4,931.68. The company’s market capitalization is GBX 56.83 billion.

A number of research firms have weighed in on AZN. Kepler Capital Markets restated a “reduce” rating and issued a GBX 3,700 ($55.06) price target on shares of AstraZeneca plc in a research note on Monday, September 14th. Bryan Garnier & Cie restated a “buy” rating and issued a GBX 5,100 ($75.89) price target on shares of AstraZeneca plc in a research note on Friday, October 23rd. HSBC restated a “buy” rating and issued a GBX 4,910 ($73.07) price target on shares of AstraZeneca plc in a research note on Wednesday, December 23rd. Handelsbanken restated an “accumulate” rating and issued a GBX 4,959.33 ($73.80) price target on shares of AstraZeneca plc in a research note on Friday, December 4th. Finally, BNP Paribas restated an “outperform” rating and issued a GBX 5,500 ($81.85) price target on shares of AstraZeneca plc in a research note on Friday, September 11th.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company’s pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.

 

Latest News

Oracle Buying Textura at a Price of $663 Million
Oracle Buying Textura at a Price of $663 Million
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
Verizon Working With Authorities On Sabotage Incidents
Verizon Working With Authorities On Sabotage Incidents
UPS Profit Increases During First Quarter by 10%
UPS Profit Increases During First Quarter by 10%
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Boeing Profit Drops on Lag in Commercial Deliveries
Boeing Profit Drops on Lag in Commercial Deliveries


Leave a Reply

 
© 2006-2017 The Vista Voice. Subscribe